This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

There is no indication that Luigi Mangione, the man charged with killing UnitedHealthcare CEO Brian Thompson, was ever a client of UnitedHealthcare, according to authorities.

President-elect Donald Trump is calling for an end to daylight saving time, a practice he described as inconvenient and costly.

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

The risk of melanoma-related death is greater for patients with primary tumors that are 0.8-1.0 mm thick than for patients with thinner tumors, data suggest.

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.